Thanks to its first-in-class FDA nod as an adjuvant therapy in 2021 and an expansion ... In the DAPA-MI trial in patients with acute myocardial infarction, AstraZeneca’s rival SGLT2 inhibitor Farxiga ...
AstraZeneca ’s AZN first-quarter 2024 core earnings of $1.03 per American depositary share (ADS) beat the Zacks Consensus Estimate of 95 cents. Core earnings of $2.06 per share rose 7% year over year ...
AstraZeneca PLC (NASDAQ: AZN) Q1 2024 Earnings Call Transcript April 25, 2024 AstraZeneca PLC misses on earnings expectations ...
Sales of AstraZeneca's (AZN) key drugs like Imfinzi and Farxiga are expected to have been boosted by approvals in new ...
The Pharma Letter provides subscribers with daily, up-to-date news, business intelligence, comment and analysis for the pharmaceutical, biotechnology and generics sectors of the health care industry, ...
In his 2016 letter to Berkshire Hathaway shareholders, legendary investor Warren Buffett wrote, “Every decade or so, dark ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback